A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, Davis
AgonOx, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Medicenna Therapeutics, Inc.
University of California, San Diego
Fate Therapeutics
Fate Therapeutics
Genocea Biosciences, Inc.
Corregene Biotechnology Co., Ltd
National Institutes of Health Clinical Center (CC)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sun Yat-sen University
National Cancer Institute (NCI)
Herlev Hospital